Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial
Katarzyna Kotfis, Igor Karolak, Kacper Lechowicz, Małgorzata Zegan-Barańska, Agnieszka Pikulska, Paulina Niedźwiedzka-Rystwej, Miłosz Kawa, Jerzy Sieńko, Aleksandra Szylińska, Magda Wiśniewska
Pharmaceuticals, doi:10.3390/ph15020200
In December 2019 the SARS-CoV-2 virus appeared in the world, mainly presenting as an acute infection of the lower respiratory tract, namely pneumonia. Nearly 10% of all patients show significant pulmonary fibrotic changes after the infection. The aim of this study was to evaluate the effectiveness and safety of potassium canrenoate in the treatment of COVID-19-associated pneumonia and pulmonary fibrosis. We performed a randomized clinical trial (RCT) of potassium canrenoate vs placebo. A total of 55 patients were randomized and 49 were included in the final analysis (24 allocated to the intervention group and 25 allocated to the control group). Patients were assessed by physical examination, lung ultrasound, CT imaging and blood samples that underwent biochemical analysis. This RCT has shown that the administration of potassium canrenoate to patients with COVID-19 induced pneumonia was not associated with shorter mechanical ventilation time, shorter passive oxygenation, shorter length of hospitalization or less fibrotic changes on CT imaging. The overall mortality rate was not significantly different between the two groups. Adverse events recorded in this study were not significantly increased by the administration of potassium canrenoate. The negative outcome of the study may be associated with the relatively small number of patients included. Any possible benefits from the use of potassium canrenoate as an antifibrotic drug in COVID-19 patients require further investigation.
Author Contributions: Conceptualization, K.K. and J.S.; Data curation, I.K., M.K. and A.S.; Formal analysis, K.K., I.K., K.L., P.N.-R., M.K. and A.S.; Funding acquisition, K.K. and M.W.; Investigation, K.K., I.K., M.Z.-B. and M.K.; Methodology, K.K., I.K., K.L., A.P., P.N.-R., J.S., A.S. and M.W.; Project administration, K.K. and I.K.; Resources, K.K.; Software, I.K. and K.L.; Supervision, K.K. and A.S.; Validation, M.Z.-B., A.P., P.N.-R. and M.W.; Visualization, I.K. and A.S.; Writing-original draft, K.K., I.K. and A.S.; Writing-review and editing, K.L., M.Z.-B., A.P., P.N.-R., M.K., J.S. and M.W. All authors have read and agreed to the published version of the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
Adams, Icheva, Deppisch, Lauer, Herrmann et al., Long-Term Pulmonal Therapy of Cystic Fibrosis-Patients with Amitriptyline, Cell. Physiol. Biochem,
doi:10.1159/000445648Alhiyari, Ata, Islam Alghizzawi, Bint I Bilal, Salih Abdulhadi et al., Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection, IDCases,
doi:10.1016/j.idcr.2020.e01041Atalay, Dogan, Aykan, Gundogdu, Keles, The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats, Singap. Med. J
Barut, Ozacmak, Turan, Sayan-Ozacmak, Aktunc, Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats, Clin. Invest. Med,
doi:10.25011/cim.v39i1.26326Cannavo, Bencivenga, Liccardo, Elia, Marzano et al., Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology, Oxid. Med. Cell. Longev,
doi:10.1155/2018/1204598Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells, Cell Rep. Med,
doi:10.1016/j.xcrm.2020.100142Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study, Lancet
Combet, Pavot, Savale, Humbert, Monnet, Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19, Eur. Respir. J,
doi:10.1183/13993003.01808-2020Edwards, Klekot, Halugan, Korchev, Follow Your Nose: A Key Clue to Understanding and Treating COVID-19, Front. Endocrinol,
doi:10.3389/fendo.2021.747744Fraser, St Noble, Hoyles, Benamore, Ho, Readily accessible CT scoring method to quantify fibrosis in IPF, BMJ Open Respir. Res,
doi:10.1136/bmjresp-2020-000584Hui, Wong, Ko, Tam, Chan et al., The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors, Chest,
doi:10.1378/chest.128.4.2247Jeon, Son, Choi, Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea, Front. Med,
doi:10.3389/fmed.2021.629176Ji, Ma, Zhou, Zhang, Lu et al., Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments, PLoS ONE,
doi:10.1371/journal.pone.0081090Jover, Matilla, Garaikoetxea, Fernández-Celis, Muntendam et al., Beneficial effects of mineralocorticoid receptor pathway blockade against endothelial inflammation induced by sars-COV-2 spike protein, Biomedicines,
doi:10.3390/biomedicines9060639Khalifa, Yosri, El-Mallah, Ghonaim, Guo et al., Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic, Phytomedicine,
doi:10.1016/j.phymed.2020.153311Kotfis, Lechowicz, Dro Żd Żal, Niedźwiedzka-Rystwej, Wojdacz et al., COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection, Pharmaceuticals,
doi:10.3390/ph14010071Kotfis, Williams Roberson, Wilson, Pun, Ely et al., COVID-19: What do we need to know about ICU delirium during the SARS-CoV-2 pandemic?, Anaesthesiol. Intensive Ther,
doi:10.5114/ait.2020.95164Kumar, Zuo, Yalavarthi, Hunker, Knight et al., SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism, Viruses,
doi:10.3390/v13112209Lechowicz, Dro Żd Żal, Machaj, Rosik, Szostak, COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection, J. Clin. Med,
doi:10.3390/jcm9061917Lian, Jin, Hao, Jia, Cai et al., Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. Influenza Other, Respi. Viruses,
doi:10.1111/irv.12758Lieber, Fernandez, Mingo, Jia, Caniga et al., Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models, Eur. J. Pharmacol,
doi:10.1016/j.ejphar.2013.08.019Loas, Le Corre, Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection, Pharmaceuticals,
doi:10.3390/ph14070691Maleszka, Kruszewski, Comparative evaluation of inhaling a single dose of furosemide or spironolactone on bronchial hyperreactivity of patients with atopic bronchial asthma, Pol. Tyg. Lek
Manivel, Lesnewski, Shamim, Carbonatto, Govindan, CLUE: COVID-19 lung ultrasound in emergency department, EMA-Emerg. Med. Australas,
doi:10.1111/1742-6723.13546Miller, Bruen, Schnaus, Zhang, Ali et al., Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: Results from a randomized controlled trial, Crit. Care,
doi:10.1186/s13054-020-03220-xNgai, Ko, Ng, To, Tong et al., The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status, Respirology,
doi:10.1111/j.1440-1843.2010.01720.xSoldati, Smargiassi, Inchingolo, Buonsenso, Perrone et al., Proposal for International Standardization of the Use of Lung Ultrasound for Patients With COVID-19, J. Ultrasound Med,
doi:10.1002/jum.15285Thille, Esteban, Fernández-Segoviano, Rodriguez, Aramburu et al., Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: A prospective cohort study of clinical autopsies, Lancet. Respir. Med,
doi:10.1016/S2213-2600(13)70053-5Umemura, Mitsuyama, Minami, Nishida, Watanabe et al., Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2021.05.055Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA
Who Team, Summary of Probable SARS Cases with Onset of Illness from 1
Wilcox, Pitt, Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?, J. Cardiovasc. Pharmacol,
doi:10.1097/FJC.0000000000000960Wu, Liu, Zhou, Yu, Li et al., 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: A prospective study, Lancet Respir. Med,
doi:10.1016/S2213-2600(21)00174-0Xu, Zhang, Dai, IL-25/IL-33/TSLP contributes to idiopathic pulmonary fibrosis: Do alveolar epithelial cells and (myo)fibroblasts matter?, Exp. Biol. Med,
doi:10.1177/1535370220915428Yavas, Yavas, Celik, Sen, Ata et al., The impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapy, Int. J. Radiat. Res,
doi:10.1016/j.jtho.2018.08.997Yu, Liu, Xu, Zhang, Lan et al., Prediction of the development of pulmonary fibrosis using serial thin-section ct and clinical features in patients discharged after treatment for COVID-19 pneumonia, Korean J. Radiol
Zaafan, Haridy, Abdelhamid, Amitriptyline attenuates bleomycin-induced pulmonary fibrosis: Modulation of the expression of NF-κβ, iNOS, and Nrf2. Naunyn-Schmiedebergs, Arch. Pharmacol,
doi:10.1007/s00210-018-1586-1Zannad, Alla, Dousset, Perez, Pitt, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales Investigators, Circulation,
doi:10.1161/01.CIR.102.22.2700Zhang, Li, Liu, Han, Ju et al., Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study, Bone Res,
doi:10.1038/s41413-020-0084-5{ 'indexed': {'date-parts': [[2022, 4, 3]], 'date-time': '2022-04-03T10:54:11Z', 'timestamp': 1648983251903},
'reference-count': 44,
'publisher': 'MDPI AG',
'issue': '2',
'license': [ { 'start': { 'date-parts': [[2022, 2, 5]],
'date-time': '2022-02-05T00:00:00Z',
'timestamp': 1644019200000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['Pharmaceuticals'],
'abstract': '<jats:p>In December 2019 the SARS-CoV-2 virus appeared in the world, mainly presenting as an '
'acute infection of the lower respiratory tract, namely pneumonia. Nearly 10% of all patients '
'show significant pulmonary fibrotic changes after the infection. The aim of this study was to '
'evaluate the effectiveness and safety of potassium canrenoate in the treatment of '
'COVID-19-associated pneumonia and pulmonary fibrosis. We performed a randomized clinical '
'trial (RCT) of potassium canrenoate vs placebo. A total of 55 patients were randomized and 49 '
'were included in the final analysis (24 allocated to the intervention group and 25 allocated '
'to the control group). Patients were assessed by physical examination, lung ultrasound, CT '
'imaging and blood samples that underwent biochemical analysis. This RCT has shown that the '
'administration of potassium canrenoate to patients with COVID-19 induced pneumonia was not '
'associated with shorter mechanical ventilation time, shorter passive oxygenation, shorter '
'length of hospitalization or less fibrotic changes on CT imaging. The overall mortality rate '
'was not significantly different between the two groups. Adverse events recorded in this study '
'were not significantly increased by the administration of potassium canrenoate. The negative '
'outcome of the study may be associated with the relatively small number of patients included. '
'Any possible benefits from the use of potassium canrenoate as an antifibrotic drug in '
'COVID-19 patients require further investigation.</jats:p>',
'DOI': '10.3390/ph15020200',
'type': 'journal-article',
'created': {'date-parts': [[2022, 2, 7]], 'date-time': '2022-02-07T01:38:40Z', 'timestamp': 1644197920000},
'page': '200',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': [ 'Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the '
'Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled '
'Clinical Trial'],
'prefix': '10.3390',
'volume': '15',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-8430-1369',
'authenticated-orcid': False,
'given': 'Katarzyna',
'family': 'Kotfis',
'sequence': 'first',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-8049-0833',
'authenticated-orcid': False,
'given': 'Igor',
'family': 'Karolak',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-0807-8510',
'authenticated-orcid': False,
'given': 'Kacper',
'family': 'Lechowicz',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-6532-9649',
'authenticated-orcid': False,
'given': 'Małgorzata',
'family': 'Zegan-Barańska',
'sequence': 'additional',
'affiliation': []},
{'given': 'Agnieszka', 'family': 'Pikulska', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-4065-3842',
'authenticated-orcid': False,
'given': 'Paulina',
'family': 'Niedźwiedzka-Rystwej',
'sequence': 'additional',
'affiliation': []},
{'given': 'Miłosz', 'family': 'Kawa', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jerzy', 'family': 'Sieńko', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-6105-5329',
'authenticated-orcid': False,
'given': 'Aleksandra',
'family': 'Szylińska',
'sequence': 'additional',
'affiliation': []},
{'given': 'Magda', 'family': 'Wiśniewska', 'sequence': 'additional', 'affiliation': []}],
'member': '1968',
'published-online': {'date-parts': [[2022, 2, 5]]},
'reference': [ {'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.1585'},
{'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30211-7'},
{'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.5114/ait.2020.100564'},
{'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/irv.12758'},
{'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.5114/ait.2020.95164'},
{'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)32656-8'},
{'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1378/chest.128.4.2247'},
{'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1440-1843.2010.01720.x'},
{ 'key': 'ref9',
'unstructured': 'World Health Organization WHO Coronavirus (COVID-19) '
'Dashboardhttps://covid19.who.int'},
{'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/jcm9061917'},
{'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(21)00174-0'},
{ 'key': 'ref12',
'series-title': 'Summary of Probable SARS Cases with Onset of Illness from 1 November '
'2002 to 31 July 2003',
'year': '2015'},
{'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41413-020-0084-5'},
{'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.25011/cim.v39i1.26326'},
{'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jtho.2018.08.997'},
{'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/01.CIR.102.22.2700'},
{'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v13112209'},
{'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fendo.2021.747744'},
{'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.1155/2018/1204598'},
{'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phymed.2020.153311'},
{'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejphar.2013.08.019'},
{'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0081090'},
{'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ph14010071'},
{ 'key': 'ref24',
'first-page': '501',
'article-title': 'The efficacy of spironolactone in the treatment of acute respiratory '
'distress syndrome-induced rats',
'volume': '51',
'author': 'Atalay',
'year': '2010',
'journal-title': 'Singap. Med. J.'},
{ 'key': 'ref25',
'first-page': '415',
'article-title': 'Comparative evaluation of inhaling a single dose of furosemide or '
'spironolactone on bronchial hyperreactivity of patients with atopic '
'bronchial asthma',
'volume': '49',
'author': 'Maleszka',
'year': '1994',
'journal-title': 'Pol. Tyg. Lek.'},
{'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00210-018-1586-1'},
{'key': 'ref27', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ph14070691'},
{'key': 'ref28', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.xcrm.2020.100142'},
{'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.1159/000445648'},
{'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/FJC.0000000000000960'},
{'key': 'ref31', 'doi-asserted-by': 'publisher', 'DOI': '10.3348/kjr.2020.0215'},
{'key': 'ref32', 'doi-asserted-by': 'publisher', 'DOI': '10.1084/jem.20110551'},
{'key': 'ref33', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/1535370220915428'},
{'key': 'ref34', 'doi-asserted-by': 'publisher', 'DOI': '10.1152/ajplung.00361.2009'},
{'key': 'ref35', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/biomedicines9060639'},
{'key': 'ref36', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2021.05.055'},
{'key': 'ref37', 'doi-asserted-by': 'publisher', 'DOI': '10.1183/13993003.01808-2020'},
{'key': 'ref38', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.idcr.2020.e01041'},
{'key': 'ref39', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13054-020-03220-x'},
{'key': 'ref40', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fmed.2021.629176'},
{'key': 'ref41', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(13)70053-5'},
{'key': 'ref42', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jum.15285'},
{'key': 'ref43', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/1742-6723.13546'},
{'key': 'ref44', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmjresp-2020-000584'}],
'container-title': ['Pharmaceuticals'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/1424-8247/15/2/200/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 2, 14]],
'date-time': '2022-02-14T09:46:40Z',
'timestamp': 1644832000000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/1424-8247/15/2/200'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 2, 5]]},
'references-count': 44,
'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2022, 2]]}},
'alternative-id': ['ph15020200'],
'URL': 'http://dx.doi.org/10.3390/ph15020200',
'relation': {},
'ISSN': ['1424-8247'],
'issn-type': [{'value': '1424-8247', 'type': 'electronic'}],
'subject': ['Drug Discovery', 'Pharmaceutical Science', 'Molecular Medicine'],
'published': {'date-parts': [[2022, 2, 5]]}}
